S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PYPL   74.34 (-3.10%)
PFE   40.01 (-1.60%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PYPL   74.34 (-3.10%)
PFE   40.01 (-1.60%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PYPL   74.34 (-3.10%)
PFE   40.01 (-1.60%)
NFLX   293.90 (-3.89%)
S&P 500   3,936.97 (-1.65%)
DOW   32,030.11 (-1.63%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PYPL   74.34 (-3.10%)
PFE   40.01 (-1.60%)
NFLX   293.90 (-3.89%)
OTCMKTS:MEOBF

Mesoblast - MEOBF Stock Forecast, Price & News

$0.74
0.00 (0.00%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.74
$0.74
50-Day Range
$0.57
$0.74
52-Week Range
$0.44
$0.86
Volume
N/A
Average Volume
1,400 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

MEOBF stock logo

About Mesoblast (OTCMKTS:MEOBF) Stock

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Receive MEOBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

MEOBF Stock News Headlines

How This Trader Banked A 97% Win Rate
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
Mesoblast Teva Starts
Mesoblast Limited (MESO) Q4 2022 Earnings Call Transcript
MindMed Appoints Schond L. Greenway As CFO
How This Trader Banked A 97% Win Rate
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
Mesoblast reports FQ3 results
Why Mesoblast Stock Is Plunging After Q4 Earnings Report?
Is Mesoblast (ASX:MSB) Using Debt Sensibly?
Mesoblast Corporate Update and Financial Results Webcast
See More Headlines
Receive MEOBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:MEOBF
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Silviu Itescu
    Chief Executive Officer, MD & Executive Director
  • Dagmar Rosa-Bjorkeson
    Chief Operating Officer
  • Andrew Chaponnel
    Chief Financial Officer & Head-Finance
  • Eric A. Rose
    Executive Director & Chief Medical Officer
  • Michael Schuster
    Head-Pharma Partnering













MEOBF Stock - Frequently Asked Questions

How have MEOBF shares performed in 2023?

Mesoblast's stock was trading at $0.5749 at the beginning of the year. Since then, MEOBF stock has increased by 28.5% and is now trading at $0.7389.
View the best growth stocks for 2023 here
.

Are investors shorting Mesoblast?

Mesoblast saw a increase in short interest in February. As of February 15th, there was short interest totaling 2,481,700 shares, an increase of 591.7% from the January 31st total of 358,800 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.
View Mesoblast's Short Interest
.

What is Mesoblast's stock symbol?

Mesoblast trades on the OTCMKTS under the ticker symbol "MEOBF."

How do I buy shares of Mesoblast?

Shares of MEOBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mesoblast's stock price today?

One share of MEOBF stock can currently be purchased for approximately $0.74.

How can I contact Mesoblast?

Mesoblast's mailing address is 55 Collins Street, Melbourne, Victoria (VIC). The official website for the company is www.mesoblast.com. The company can be reached via phone at (139) 639-6036.

This page (OTCMKTS:MEOBF) was last updated on 3/22/2023 by MarketBeat.com Staff